Schizophrenia Research最新文献

英文中文

Assessing measurement invariance of paranoia scales across racial and ethnic groups in the U.S. 美国种族和民族偏执狂量表测量的不变性评估

IF 3.5 2区医学 Q1 PSYCHIATRY

Schizophrenia Research

Pub Date : 2025-11-06 DOI: 10.1016/j.schres.2025.10.026

Thomas A. Bart , Megan M. Hricovec , Shealen Taylor , Wesley Amlong , David C. Cicero

Paranoid ideation relates to a mistrust or suspicion of other people and their motives and may be especially influenced by environmental and psychosocial factors. Historically marginalized populations consistently endorse higher levels of paranoid ideation than Non-Hispanic White individuals, but it is unclear whether these differences can be attributed to measurement bias or if they represent genuine between-group differences in the latent construct. The current study aimed to examine the measurement invariance of five common paranoia measures. Participants included Non-Hispanic White (n = 308), Black American (n = 299), and Hispanic (n = 281) groups recruited from the general population. Scales included the Revised-Green Paranoid Thoughts Scale (R-GPTS), Paranoia Scale (PS), Persecution and Deservedness Scale (PaDS), Paranoia/Suspiciousness Questionnaire (PSQ), and the Personality Inventory for the DSM-5 (PID-5) Suspiciousness facet scale. Measurement invariance analyses indicated the R-GPTS, PS, PaDS, PID-5 Suspiciousness facet, and PSQ Negative Mood/Withdrawal and Perceived Hardship/Resentment subscales showed configural, metric, and scalar invariance, while the Interpersonal Suspiciousness/Hostility and Mistrust/Wariness subscales lacked scalar invariance. Black American participants had higher mean scores on all invariant measures, followed by Hispanic and Non-Hispanic White participants. For the scales that displayed scalar invariance, these results are unlikely to be attributable to measurement bias, and instead likely reflect cultural and potentially adaptive responses to the complex relationships between cultural, social, and economic factors. To better understand how demographic variables and social determinants of health may influence paranoid ideation in diverse populations, future research should incorporate these variables into measurement invariance and group difference analyses.

偏执观念与对他人及其动机的不信任或怀疑有关，尤其可能受到环境和社会心理因素的影响。历史上被边缘化的人群比非西班牙裔白人的偏执观念水平始终更高，但目前尚不清楚这些差异是否可以归因于测量偏差，或者它们是否代表了潜在结构的真正组间差异。本研究旨在检验五种常见偏执狂测量的测量不变性。参与者包括从普通人群中招募的非西班牙裔白人（n = 308）、美国黑人（n = 299）和西班牙裔（n = 281）组。量表包括修订绿色偏执思想量表（R-GPTS）、偏执量表（PS）、迫害与罪有应得量表（PaDS）、偏执/怀疑问卷（PSQ）和DSM-5 （PID-5）怀疑面人格量表。测量不变性分析表明，R-GPTS、PS、PaDS、PID-5怀疑面和PSQ消极情绪/退缩和感知困难/怨恨分量表具有构形、度量和标量不变性，而人际怀疑/敌意和不信任/警惕分量表缺乏标量不变性。美国黑人参与者在所有不变指标上的平均得分较高，其次是西班牙裔和非西班牙裔白人参与者。对于显示标量不变性的量表，这些结果不太可能归因于测量偏差，而可能反映了文化和对文化、社会和经济因素之间复杂关系的潜在适应性反应。为了更好地了解人口统计变量和健康的社会决定因素如何影响不同人群的偏执观念，未来的研究应将这些变量纳入测量不变性和群体差异分析。

{"title":"Assessing measurement invariance of paranoia scales across racial and ethnic groups in the U.S.","authors":"Thomas A. Bart , Megan M. Hricovec , Shealen Taylor , Wesley Amlong , David C. Cicero","doi":"10.1016/j.schres.2025.10.026","DOIUrl":"10.1016/j.schres.2025.10.026","url":null,"abstract":"<div><div>Paranoid ideation relates to a mistrust or suspicion of other people and their motives and may be especially influenced by environmental and psychosocial factors. Historically marginalized populations consistently endorse higher levels of paranoid ideation than Non-Hispanic White individuals, but it is unclear whether these differences can be attributed to measurement bias or if they represent genuine between-group differences in the latent construct. The current study aimed to examine the measurement invariance of five common paranoia measures. Participants included Non-Hispanic White (<em>n</em> = 308), Black American (<em>n</em> = 299), and Hispanic (<em>n</em> = 281) groups recruited from the general population. Scales included the Revised-Green Paranoid Thoughts Scale (R-GPTS), Paranoia Scale (PS), Persecution and Deservedness Scale (PaDS), Paranoia/Suspiciousness Questionnaire (PSQ), and the Personality Inventory for the DSM-5 (PID-5) Suspiciousness facet scale. Measurement invariance analyses indicated the R-GPTS, PS, PaDS, PID-5 Suspiciousness facet, and PSQ Negative Mood/Withdrawal and Perceived Hardship/Resentment subscales showed configural, metric, and scalar invariance, while the Interpersonal Suspiciousness/Hostility and Mistrust/Wariness subscales lacked scalar invariance. Black American participants had higher mean scores on all invariant measures, followed by Hispanic and Non-Hispanic White participants. For the scales that displayed scalar invariance, these results are unlikely to be attributable to measurement bias, and instead likely reflect cultural and potentially adaptive responses to the complex relationships between cultural, social, and economic factors. To better understand how demographic variables and social determinants of health may influence paranoid ideation in diverse populations, future research should incorporate these variables into measurement invariance and group difference analyses.</div></div>","PeriodicalId":21417,"journal":{"name":"Schizophrenia Research","volume":"286 ","pages":"Pages 125-131"},"PeriodicalIF":3.5,"publicationDate":"2025-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145467585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Quality of life in patients with schizophrenia: A systematic review and meta-analysis of case-control studies 精神分裂症患者的生活质量：病例对照研究的系统回顾和荟萃分析。

IF 3.5 2区医学 Q1 PSYCHIATRY

Schizophrenia Research

Pub Date : 2025-11-05 DOI: 10.1016/j.schres.2025.10.019

Yu-Cheng Wang , Hui-Ying Fan , Qian-Hua Huang , Xuan-Chen Liu , Yi-Ran Huang , Zhaohui Su , Teris Cheung , Gabor S. Ungvari , Yuan Feng , Gang Wang , Chee H. Ng , Yu-Tao Xiang

Background

Although numerous studies have examined the impact of schizophrenia on quality of life (QoL), the results have been mixed. This meta-analysis compared QoL across various domains between schizophrenia patients and healthy controls and identified the moderators of group differences.

Methods

A meta-analysis of case-control studies was conducted following PRISMA guidelines. Major international databases (PubMed, Web of Science, EMBASE and PsycINFO) and Chinese databases (CNKI and Wanfang) were searched from their inception to December 2024. Studies comparing QoL between patients with schizophrenia and healthy controls using standardized validated instruments (e.g., WHOQOL, SF-36) were included. Standardized mean differences (SMDs) were calculated using a random-effects model. Subgroup and meta-regression analyses were performed to explore the moderators of group differences.

Results

Thirty-six studies (5664 patients; 5042 controls) met the inclusion criteria, revealing significant QoL impairment in patients across all domains. Deficits were most pronounced in the physical domain (WHOQOL: SMD = −1.52; SF-36: SMD = −1.16; GQOLI: SMD = −2.38) and social domain (WHOQOL: SMD = −1.33; SF-36: SMD = −1.24; GQOLI: SMD = −2.56), with notable impairment also in psychological (WHOQOL: SMD = −1.11) and environmental (WHOQOL: SMD = −0.87) domains. Meta-regression demonstrated that more severe negative symptoms score (β = −0.051, p = 0.043) and greater general psychopathology (β = −0.038, p = 0.049) were significantly associated with poorer environmental QoL.

Conclusion

This meta-analysis demonstrated that patients with schizophrenia have significant QoL impairment across multiple domains, particularly in the physical and social functioning domains. These findings highlight the need to address clinical moderators to develop patient-centered interventions.

背景：虽然许多研究已经调查了精神分裂症对生活质量（QoL）的影响，但结果却喜忧参半。本荟萃分析比较了精神分裂症患者和健康对照者在各个领域的生活质量，并确定了组间差异的调节因子。方法：根据PRISMA指南对病例对照研究进行荟萃分析。主要国际数据库（PubMed, Web of Science， EMBASE和PsycINFO）和中国数据库（CNKI和万方）从成立到2024年12月进行了检索。采用标准化的验证仪器（如WHOQOL， SF-36）比较精神分裂症患者和健康对照者的生活质量。采用随机效应模型计算标准化平均差（SMDs）。进行亚组和元回归分析以探索组间差异的调节因子。结果：36项研究（5664例患者；5042例对照）符合纳入标准，揭示了所有领域患者的显著生活质量损害。缺陷在物理领域（WHOQOL: SMD = -1.52; SF-36: SMD = -1.16; GQOLI: SMD = -2.38）和社会领域（WHOQOL: SMD = -1.33; SF-36: SMD = -1.24; GQOLI: SMD = -2.56）最为明显，心理领域（WHOQOL: SMD = -1.11）和环境领域（WHOQOL: SMD = -0.87）也有显著的缺陷。meta回归显示，阴性症状评分越重（β = -0.051, p = 0.043）和一般精神病理评分越高（β = -0.038, p = 0.049）与环境生活质量越差相关。结论：本荟萃分析表明，精神分裂症患者在多个领域存在显著的生活质量损害，特别是在身体和社会功能领域。这些发现强调了解决临床调节因素以开发以患者为中心的干预措施的必要性。

{"title":"Quality of life in patients with schizophrenia: A systematic review and meta-analysis of case-control studies","authors":"Yu-Cheng Wang , Hui-Ying Fan , Qian-Hua Huang , Xuan-Chen Liu , Yi-Ran Huang , Zhaohui Su , Teris Cheung , Gabor S. Ungvari , Yuan Feng , Gang Wang , Chee H. Ng , Yu-Tao Xiang","doi":"10.1016/j.schres.2025.10.019","DOIUrl":"10.1016/j.schres.2025.10.019","url":null,"abstract":"<div><h3>Background</h3><div>Although numerous studies have examined the impact of schizophrenia on quality of life (QoL), the results have been mixed. This meta-analysis compared QoL across various domains between schizophrenia patients and healthy controls and identified the moderators of group differences.</div></div><div><h3>Methods</h3><div>A meta-analysis of case-control studies was conducted following PRISMA guidelines. Major international databases (PubMed, Web of Science, EMBASE and PsycINFO) and Chinese databases (CNKI and Wanfang) were searched from their inception to December 2024. Studies comparing QoL between patients with schizophrenia and healthy controls using standardized validated instruments (e.g., WHOQOL, SF-36) were included. Standardized mean differences (SMDs) were calculated using a random-effects model. Subgroup and meta-regression analyses were performed to explore the moderators of group differences.</div></div><div><h3>Results</h3><div>Thirty-six studies (5664 patients; 5042 controls) met the inclusion criteria, revealing significant QoL impairment in patients across all domains. Deficits were most pronounced in the physical domain (WHOQOL: SMD = −1.52; SF-36: SMD = −1.16; GQOLI: SMD = −2.38) and social domain (WHOQOL: SMD = −1.33; SF-36: SMD = −1.24; GQOLI: SMD = −2.56), with notable impairment also in psychological (WHOQOL: SMD = −1.11) and environmental (WHOQOL: SMD = −0.87) domains. Meta-regression demonstrated that more severe negative symptoms score (β = −0.051, <em>p</em> = 0.043) and greater general psychopathology (β = −0.038, <em>p</em> = 0.049) were significantly associated with poorer environmental QoL.</div></div><div><h3>Conclusion</h3><div>This meta-analysis demonstrated that patients with schizophrenia have significant QoL impairment across multiple domains, particularly in the physical and social functioning domains. These findings highlight the need to address clinical moderators to develop patient-centered interventions.</div></div>","PeriodicalId":21417,"journal":{"name":"Schizophrenia Research","volume":"286 ","pages":"Pages 112-124"},"PeriodicalIF":3.5,"publicationDate":"2025-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145459730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Guest editorial: Social determinants of health in the psychosis spectrum 客座评论：精神病谱系中健康的社会决定因素。

IF 3.5 2区医学 Q1 PSYCHIATRY

Schizophrenia Research

Pub Date : 2025-11-04 DOI: 10.1016/j.schres.2025.10.023

Dilip V. Jeste , Michael F. Green

引用次数: 0

Exploring hippocampal dysfunction in schizophrenia with pluripotent stem cell models 用多能干细胞模型研究精神分裂症海马功能障碍。

IF 3.5 2区医学 Q1 PSYCHIATRY

Schizophrenia Research

Pub Date : 2025-11-04 DOI: 10.1016/j.schres.2025.10.022

Deepak Kaji

Schizophrenia is a complex neurodevelopmental disorder characterized by widespread cognitive and behavioral impairments, with the hippocampus playing a critical role in its pathophysiology. While traditional approaches such as animal models and postmortem studies have provided valuable insights, they fall short in capturing the human-specific and developmental features of the disease. Human pluripotent stem cell (hPSC) models, particularly 3D brain organoids, represent a powerful new tool for investigating the cellular and circuit-level mechanisms underlying schizophrenia. Although cortical and striatal organoids have been increasingly utilized in psychiatric research, hippocampal organoid models remain underdeveloped and underused. This review outlines the developmental basis of hippocampal dysfunction in schizophrenia and discusses the emergence of hPSC-derived hippocampal organoids and assembloids as novel in vitro systems. We highlight key findings from the limited studies using hippocampal differentiations in schizophrenia, explore their potential to model region-specific circuitry (e.g., DG-CA3, cortico-hippocampal, and hippocampalstriatal networks), and identify major technical challenges such as the absence of CA1/CA2 subfields, limited vascularization, and the need for microglial integration. Finally, we propose future directions to refine these models and leverage them for mechanistic discovery and therapeutic screening. By integrating genetic, imaging, and developmental perspectives, this review positions hippocampal organoid technology as a promising yet underutilized platform for advancing our understanding of schizophrenia's neurodevelopmental origins.

精神分裂症是一种复杂的神经发育障碍，以广泛的认知和行为障碍为特征，海马体在其病理生理中起着关键作用。虽然动物模型和死后研究等传统方法提供了有价值的见解，但它们在捕捉该疾病的人类特异性和发育特征方面存在不足。人类多能干细胞（hPSC）模型，特别是3D脑类器官，代表了研究精神分裂症的细胞和电路水平机制的强大新工具。尽管皮层和纹状体类器官在精神病学研究中的应用越来越多，但海马类器官模型仍然不发达和未充分利用。本文概述了精神分裂症海马功能障碍的发展基础，并讨论了hpsc衍生的海马类器官和集合体作为新型体外系统的出现。我们强调了在精神分裂症中使用海马分化的有限研究中的关键发现，探索了它们在模拟区域特异性电路（例如，DG-CA3，皮质-海马和海马纹状体网络）方面的潜力，并确定了主要的技术挑战，如缺乏CA1/CA2亚场，有限的血管化和需要小胶质细胞整合。最后，我们提出了完善这些模型的未来方向，并利用它们进行机制发现和治疗筛选。通过整合遗传学、影像学和发育方面的观点，本综述将海马类器官技术定位为一个有前途但尚未充分利用的平台，以促进我们对精神分裂症神经发育起源的理解。

{"title":"Exploring hippocampal dysfunction in schizophrenia with pluripotent stem cell models","authors":"Deepak Kaji","doi":"10.1016/j.schres.2025.10.022","DOIUrl":"10.1016/j.schres.2025.10.022","url":null,"abstract":"<div><div>Schizophrenia is a complex neurodevelopmental disorder characterized by widespread cognitive and behavioral impairments, with the hippocampus playing a critical role in its pathophysiology. While traditional approaches such as animal models and postmortem studies have provided valuable insights, they fall short in capturing the human-specific and developmental features of the disease. Human pluripotent stem cell (hPSC) models, particularly 3D brain organoids, represent a powerful new tool for investigating the cellular and circuit-level mechanisms underlying schizophrenia. Although cortical and striatal organoids have been increasingly utilized in psychiatric research, hippocampal organoid models remain underdeveloped and underused. This review outlines the developmental basis of hippocampal dysfunction in schizophrenia and discusses the emergence of hPSC-derived hippocampal organoids and assembloids as novel in vitro systems. We highlight key findings from the limited studies using hippocampal differentiations in schizophrenia, explore their potential to model region-specific circuitry (e.g., DG-CA3, cortico-hippocampal, and hippocampalstriatal networks), and identify major technical challenges such as the absence of CA1/CA2 subfields, limited vascularization, and the need for microglial integration. Finally, we propose future directions to refine these models and leverage them for mechanistic discovery and therapeutic screening. By integrating genetic, imaging, and developmental perspectives, this review positions hippocampal organoid technology as a promising yet underutilized platform for advancing our understanding of schizophrenia's neurodevelopmental origins.</div></div>","PeriodicalId":21417,"journal":{"name":"Schizophrenia Research","volume":"286 ","pages":"Pages 100-109"},"PeriodicalIF":3.5,"publicationDate":"2025-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145452913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Experiential science in schizophrenia research: Our new dedicated section. 暂时移除：精神分裂症研究中的经验科学：我们新的专用部分

IF 3.5 2区医学 Q1 PSYCHIATRY

Schizophrenia Research

Pub Date : 2025-11-03 DOI: 10.1016/j.schres.2025.10.024

Paola Dazzan, Lena Palaniyappan

引用次数: 0

Corrigendum to “Jang YJ, et al. Characterizing the relationship between personality dimensions and psychosis-specific clinical characteristics” [Schizophr Res. 276 (2025) 88–96 10.1016/j.schres.2025.01.002 (Epub ahead of print, PMID: 39864301, Jan 25)] “张玉杰等”的勘误表。人格维度与精神病特异性临床特征的关系表征[j].精神分裂症。276 (2025)88-96 10.1016/j.schres. 2015.01.002 （Epub ahead of print, PMID: 39864301, 1月25日）。

IF 3.5 2区医学 Q1 PSYCHIATRY

Schizophrenia Research

Pub Date : 2025-11-01 DOI: 10.1016/j.schres.2025.05.005

Y.J. Jang , W. Yassin , R. Mesholam-Gately , E.S. Gershon , S. Keedy , G.D. Pearlson , C.A. Tamminga , J. McDowell , D.A. Parker , K. Sauer , B. Clementz , M.S. Keshavan

引用次数: 0

The hippocampus: At the nexus of risk and resilience for schizophrenia 海马体：精神分裂症风险和恢复力的关系

IF 3.5 2区医学 Q1 PSYCHIATRY

Schizophrenia Research

Pub Date : 2025-11-01 Epub Date: 2025-09-23 DOI: 10.1016/j.schres.2025.09.016

Katherine S.F. Damme

引用次数: 0

Does adjunctive electro-convulsive therapy improve the speed of treatment response in schizophrenia? A systematic review and week-by-week meta-analyses of controlled clinical trials 辅助电痉挛治疗是否能提高精神分裂症的治疗反应速度？对照临床试验的系统回顾和每周荟萃分析。

IF 3.5 2区医学 Q1 PSYCHIATRY

Schizophrenia Research

Pub Date : 2025-11-01 Epub Date: 2025-09-17 DOI: 10.1016/j.schres.2025.08.018

Makarand Pantoji, Srinivas Balachander, Palash Prajapati, Shyam Sundar Arumugham, Ganesan Venkatasubramanian, Jagadisha Thirthalli

Background

Electroconvulsive therapy (ECT) is sometimes recommended in patients with schizophrenia to hasten clinical response. However, there is limited research comparing the speed of response between ECT in combination with antipsychotic medication versus antipsychotics alone. We conducted a systematic review and meta-analyses of week-by-week clinical response to examine whether ECT augmentation leads to faster improvement in psychotic symptoms in patients with schizophrenia.

Methods

We searched PubMed/Medline and Cochrane Library for controlled trials which compared the combination of ECT and antipsychotic drugs (ECT + AP) with antipsychotic drugs alone (AP) in patients with schizophrenia. We performed a pairwise random-effects meta-analysis for each time point. Hedge's g was used as the effect size estimate. A multivariate mixed-effects meta-analysis was performed to test whether the response speed was different between the groups.

Results

Of a total of 4899 search results, 12 studies were included. In five of them, the authors reported that the ECT + AP group responded faster. Pairwise meta-analysis for each week showed that ECT + AP group was significantly superior to the AP group at week 1 [g = 0.897 (95 % CI 0.236–1.557)], week 2 [g = 0.986 (95 % CI 0.273–1.700)], and week 4 [g = 1.587 (95 % CI 0.180–2.995)], but not after that. The multivariate mixed-effects meta-analysis also showed a significant Group*Week interaction [B = 0.17(95 % CI 0.10–0.24), p < 0.001].

Conclusions

ECT augmentation in schizophrenia, given its potential for faster response, may have some advantage in acutely ill patients, particularly those requiring hospitalization and needing rapid symptom resolution.

背景：电痉挛疗法（ECT）有时被推荐用于精神分裂症患者，以加速临床反应。然而，比较ECT联合抗精神病药物与单独抗精神病药物的反应速度的研究有限。我们对每周的临床反应进行了系统回顾和荟萃分析，以检验ECT增强是否能更快地改善精神分裂症患者的精神病症状。方法：检索PubMed/Medline和Cochrane Library，检索比较ECT联合抗精神病药物（ECT + AP）与单独抗精神病药物（AP）治疗精神分裂症患者的对照试验。我们对每个时间点进行两两随机效应荟萃分析。使用Hedge’s g作为效应量估计。采用多变量混合效应meta分析检验两组间反应速度是否存在差异。结果：在4899个检索结果中，纳入了12项研究。在其中的5例中，作者报告说ECT + AP组反应更快。各周的两两荟萃分析显示，ECT + AP组在第1周[g = 0.897 (95% CI 0.236-1.557)]、第2周[g = 0.986 (95% CI 0.273-1.700)]和第4周[g = 1.587 (95% CI 0.180-2.995)]显著优于AP组，之后则无显著差异。多变量混合效应荟萃分析也显示了显著的组与周相互作用[B = 0.17(95% CI 0.10-0.24), p]。结论：ECT增强治疗精神分裂症，鉴于其潜在的更快的反应，可能对急症患者有一些优势，特别是那些需要住院治疗和需要快速缓解症状的患者。

{"title":"Does adjunctive electro-convulsive therapy improve the speed of treatment response in schizophrenia? A systematic review and week-by-week meta-analyses of controlled clinical trials","authors":"Makarand Pantoji, Srinivas Balachander, Palash Prajapati, Shyam Sundar Arumugham, Ganesan Venkatasubramanian, Jagadisha Thirthalli","doi":"10.1016/j.schres.2025.08.018","DOIUrl":"10.1016/j.schres.2025.08.018","url":null,"abstract":"<div><h3>Background</h3><div>Electroconvulsive therapy (ECT) is sometimes recommended in patients with schizophrenia to hasten clinical response. However, there is limited research comparing the speed of response between ECT in combination with antipsychotic medication versus antipsychotics alone. We conducted a systematic review and meta-analyses of week-by-week clinical response to examine whether ECT augmentation leads to faster improvement in psychotic symptoms in patients with schizophrenia.</div></div><div><h3>Methods</h3><div>We searched PubMed/Medline and Cochrane Library for controlled trials which compared the combination of ECT and antipsychotic drugs (ECT + AP) with antipsychotic drugs alone (AP) in patients with schizophrenia. We performed a pairwise random-effects meta-analysis for each time point. Hedge's g was used as the effect size estimate. A multivariate mixed-effects meta-analysis was performed to test whether the response speed was different between the groups.</div></div><div><h3>Results</h3><div>Of a total of 4899 search results, 12 studies were included. In five of them, the authors reported that the ECT + AP group responded faster. Pairwise meta-analysis for each week showed that ECT + AP group was significantly superior to the AP group at week 1 [g = 0.897 (95 % CI 0.236–1.557)], week 2 [g = 0.986 (95 % CI 0.273–1.700)], and week 4 [g = 1.587 (95 % CI 0.180–2.995)], but not after that. The multivariate mixed-effects meta-analysis also showed a significant Group*Week interaction [B = 0.17(95 % CI 0.10–0.24), <em>p</em> < 0.001].</div></div><div><h3>Conclusions</h3><div>ECT augmentation in schizophrenia, given its potential for faster response, may have some advantage in acutely ill patients, particularly those requiring hospitalization and needing rapid symptom resolution.</div></div>","PeriodicalId":21417,"journal":{"name":"Schizophrenia Research","volume":"285 ","pages":"Pages 114-123"},"PeriodicalIF":3.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145086916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to “Effect of treatment with paliperidone palmitate versus oral antipsychotics on frontal lobe intracortical myelin volume in participants with recent-onset schizophrenia: Magnetic resonance imaging results from the DREaM study” [Schizophr Res. 255 (2023) 195–202] “棕榈酸帕利哌酮与口服抗精神病药物治疗对新近发作的精神分裂症患者额叶皮质内髓磷脂体积的影响：来自DREaM研究的磁共振成像结果”[精神分裂症，255(2023)195-202]。

IF 3.5 2区医学 Q1 PSYCHIATRY

Schizophrenia Research

Pub Date : 2025-11-01 Epub Date: 2025-06-06 DOI: 10.1016/j.schres.2025.05.023

T.A. Tishler, B.M. Ellingson, G. Salvadore, P. Baker, I. Turkoz, K.L. Subotnik, C. de la Fuente-Sandoval, K.H. Nuechterlein, L. Alphs

引用次数: 0

Corrigendum to “Psychopathology trajectories and relapse in first episode schizophrenia with assured long-acting injectable adherence over 24 months” [Schizophr. Res. volume 276 (2025), 8–14/article number] “精神病理轨迹和首次发作精神分裂症的复发与24个月以上的长效注射依从性”的更正[精神分裂症。Res.第276卷（2025），8-14/条数]。

IF 3.5 2区医学 Q1 PSYCHIATRY

Schizophrenia Research

Pub Date : 2025-11-01 DOI: 10.1016/j.schres.2025.04.005

Smit Retha, Luckhoff Hilmar, Phahladira Lebogang, Kilian Sanja, Emsley Robin, Asmal Laila

引用次数: 0

首页上一页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Schizophrenia Research

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀